Health & Environmental Research Online (HERO)


Print Feedback Export to File
2744989 
Journal Article 
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis 
Cortelazzo, S; Finazzi, G; Ruggeri, M; Vestri, O; Barbui, T; Et al 
1995 
1 
New England Journal of Medicine
ISSN: 0028-4793
EISSN: 1533-4406 
IPA/95/1077197 
Engl 
REF 19 
English 
IPA COPYRIGHT: ASHP The efficacy of hydroxyurea in preventing thrombosis in high risk patients with essential thrombocythemia was studied in 114 patients (ages 40-85 yr) who were randomly assigned to receive hydroxyurea (Oncocarbide) or no myelosuppressive therapy (controls). The dose of hydroxyurea was 15 mg/kg/day; thereafter, a maintenance dose of the drug was administered to maintain the platelet count below 600,000/cu mm without lowering the white-cell count below 4000/cu mm. Results showed that 2 patients treated with hydroxyurea had thrombotic episodes, whereas 14 patients in the control group had thrombotic episodes. The difference was statistically significant.